Attention Deficit Hyperactivity Disorder, or ADHD, is a psychiatric pathology for which diagnosis has increased exponentially over the last 20 years. In fact, current estimates suggest that this disorder affects between 2% and 5% of children in Spain, an average of one or two children per classroom, and up to 4% of the adult population. Despite these high incidence rates, controversy surrounds the treatment of this pathology and the therapeutic approach to it. This varies widely depending on each patient, the symptoms they present and their intensity. For this reason, experts are continuing to investigate different components and substances that may be capable of providing new treatment opportunities for patients diagnosed with ADHD.